Group Room Radio Goes International

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.